Voriconazole
| Drug Category | Drug | IHD Dosing | Administration Timing Around HD Session |
|---|---|---|---|
| Antifungals | Voriconazole | 200mg PO Q12H; IV not recommended | Administer Anytime During HD |
Molecular Weight (Da) | Excreted Unchanged (%) | Normal Half-Life (Hours) | ESRD Half-Life (Hours) | Plasma Protein Binding (%) | Volume of Distribution (L/kg) | Dialytic Plasma Clearance (ml/min) | % Dialyzed |
|---|---|---|---|---|---|---|---|
| 349 | <2 | 6-24 | N/A | 60 | 4.6 | 66.7 | 10 (high flux) |
References:
- Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians;2007.
- Cota J, Burgess D. Antifungal Dose Adjustment in Renal and Hepatic Dysfunction : Pharmacokinetic and Pharmacodynamic Considerations. Curr Fungal Infect Rep 2010; 4, 120-128.
- DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB00582
- Hafner V, Czock D, Burhenne J et al. Pharmacokinetics of sulfobutylether-beta-cyclodextrin and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodiafiltration. Antimicrobial agents and chemotherapy 2010; 54(6), 2596-602.
- Heintz B, Matzke G, Dager W. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy 2009; 29(5), 562-77.
- Ullmann A. Pharmacological Aspects of the New Triazole Voriconazole. Annals of Hematology, S50.